Alpha Cancer Technologies Inc., (ACT) is a private clinical stage biotechnology company with products under development in oncology and auto-immune disease indications. The company’s drug products use our proprietary recombinant human alpha fetoprotein (AFP) with unique immuno-oncology properties.On…
Alpha Cancer Technologies Inc., (ACT) is a private clinical stage biotechnology company with products under development in oncology and auto-immune disease indications. The company’s drug products use our proprietary recombinant human alpha fetoprotein (AFP) with unique immuno-oncology properties.
One of the largest US biotech companies recently purchased a 14% equity stake in ACT for US $7.5 million as part of a larger financing with institutional and private investors.
Team (1)
Sectors Alpha Cancer Technologies serves:
Life Sciences
Join Axial's Private M&A Platform
Alpha Cancer Technologies connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
